Intra-Cellular Return on Sales Trend from 2010 to 2022

ITCI
 Stock
  

USD 59.19  2.86  5.08%   

Intra-Cellular Ther Return on Sales is decreasing over the last several years with stable swings. Return on Sales is predicted to flatten to -3.66. During the period from 2010 to 2022 Intra-Cellular Ther Return on Sales regressed destribution of quarterly values had mean deviationof 682.93 and mean square error of  832,274. Intra-Cellular Ther Operating Expenses is most likely to increase significantly in the upcoming years. The last year's value of Operating Expenses was reported at 361.46 Million. The current Revenues is estimated to increase to about 90.4 M, while Consolidated Income is projected to decrease to (291.6 M).
  
Check Intra-Cellular Ther financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intra-Cellular main balance sheet or income statement drivers, such as Direct Expenses of 8.7 M, Cost of Revenue of 7.1 M or Gross Profit of 81.8 M, as well as many exotic indicators such as Calculated Tax Rate of 0.52, PPandE Turnover of 47.73 or Receivables Turnover of 6.23. Intra-Cellular financial statements analysis is a perfect complement when working with Intra-Cellular Ther Valuation or Volatility modules. It can also supplement Intra-Cellular Ther's financial leverage analysis and stock options assessment as well as various Intra-Cellular Ther Technical models . Please see the analysis of Intra-Cellular Ther Correlation against competitors.

Intra-Cellular Return on Sales Breakdown

Showing smoothed Return on Sales of Intra-Cellular Ther with missing and latest data points interpolated. Return on Sales is a ratio to evaluate a company's operational efficiency; calculated by dividing Earning Before Interest and Taxes EBIT by Revenues. ROS is often a component of DuPont ROE analysis.Intra-Cellular Ther's Return on Sales historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Intra-Cellular Ther's overall financial position and show how it may be relating to other accounts over time.
Return on Sales10 Years Trend
Decreasing
Stable
   Return on Sales   
Share
       Timeline  

Intra-Cellular Return on Sales Regression Statistics

Arithmetic Mean(527.38)
Coefficient Of Variation(171.92)
Mean Deviation 682.93
Median(9.95)
Standard Deviation 906.69
Sample Variance 822,095
Range 2,438
R-Value(0.27)
Mean Square Error 832,274
R-Squared 0.07
Significance 0.38
Slope(62.46)
Total Sum of Squares 9,865,137

Intra-Cellular Return on Sales History

2012 -5.25
2013 -9.59
2014 -53.15
2015 -1146.97
2016 -348.72
2017 -402.03
2018 -2437.11
2020 -9.95
2021 -3.39
2022 -3.66

About Intra-Cellular Ther Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Intra-Cellular Ther income statement, its balance sheet, and the statement of cash flows. Intra-Cellular Ther investors use historical funamental indicators, such as Intra-Cellular Ther's Return on Sales, to determine how well the company is positioned to perform in the future. Although Intra-Cellular Ther investors may use each financial statement separately, they are all related. The changes in Intra-Cellular Ther's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Intra-Cellular Ther's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Intra-Cellular Ther Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Intra-Cellular Ther. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Return on Sales(3.39) (3.66) 
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Intra-Cellular Ther without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bond Analysis Now

   

Bond Analysis

Evaluate and analyze corporate bonds as a potential investment for your portfolios.
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Intra-Cellular Ther using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Intra-Cellular Ther Correlation against competitors. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.6 B
Quarterly Revenue Growth YOY
1.2
Return On Assets
-0.25
Return On Equity
-0.43
The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.